Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2026
Grifols releases quarterly earnings results
Grifols reported quarterly earnings per share of $0.46, exceeding analysts’ consensus estimate of $0.32 by $0.14.
2022
Grifols partners with Feeding America for hunger-relief drive
Grifols announced a partnership with Feeding America to collect nonperishable food and raise money for local member food banks across the United States.
2022
Grifols acquires Winnipeg plasma donation center
Grifols announced that its subsidiary Grifols Canada Therapeutics Inc had acquired Prometic Plasma Resources Inc's Winnipeg donation center from Kedrion for USD 4 million in cash.
2021
Grifols announces agreement to acquire Tiancheng Germany
Grifols announced an agreement with Tiancheng International Investment Ltd. to acquire all shares of Tiancheng (Germany) Pharmaceutical Holdings AG, which owns 89.88% of Biotest's ordinary shares and 1.08% of its preferred shares. The transaction is subject to regulatory approvals and other conditions.
2021
Grifols begins commercializing new HyperHEP B formulation
Grifols began commercializing a new formulation of HyperHEP B, its hepatitis B immune globulin for postexposure prophylaxis.
2020
Grifols announces planned acquisition of plasma assets from GC Pharma
Grifols announced that it had executed purchase arrangements with GC Pharma to acquire a Montreal plasma fractionation facility, two purification facilities and 11 U.S. plasma collection centers for US$460 million.
2020
Palette Life Sciences expands distribution for Deflux and Solesta
Palette Life Sciences announced expanded commercial access for Deflux and Solesta in more than 20 countries through five distributors, alongside direct sales in Cyprus, Greece, Hungary and Portugal.
2020
Grifols announces collaboration with U.S. public health agencies on COVID-19 treatment
Grifols announced a formal collaboration with BARDA, the FDA and other federal public health agencies to collect convalescent plasma, process it into hyperimmune globulin and support studies to assess its potential as a COVID-19 treatment.